Congo-Kinshasa: Three New Ebola Vaccines Are Being Developed. an Infectious Disease Expert Explains
Three new Ebola vaccine candidates are being developed to combat the Bundibugyo virus in the Democratic Republic of the Congo and Uganda. Recent funding of up to $62 million aims to fast-track their development and clinical trials. Health authorities have also reported a decrease in confirmed Ebola cases and deaths in the region.
- ▪The Coalition for Epidemic Preparedness Innovations is providing funding to accelerate the development of Ebola vaccines.
- ▪Currently, there are two approved Ebola vaccines, but they are not effective against the Bundibugyo virus circulating in the region.
- ▪The three new vaccine candidates include one from the International AIDS Vaccine Initiative, one from Moderna, and one from the University of Oxford.
Opening excerpt (first ~120 words) tap to expand
When it comes to Ebola outbreaks, it's not often we have two pieces of good news in one week. First, we heard there's new funding of up to US$62 million to fast-track the development of vaccine candidates against the type of virus circulating in the Democratic Republic of the Congo (DRC) and neighbouring Uganda. Then, we heard authorities had downgraded the confirmed numbers of Ebola deaths and cases in the region. Keep up with the latest headlines on WhatsApp | LinkedIn As of June 2 local time, DRC health authorities reported 344 confirmed cases, including 60 confirmed related deaths. Uganda has reported 15 confirmed cases, including one death. Previously, suspected cases in the region were more than 1,000.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at AllAfrica.
Discussion
0 commentsMore from AllAfrica
